Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRG2 | P18507 | 1/20 | 0.63 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.63 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.63 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.63 |
| ▸ | GRM5 | P41594 | 2/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | ABL1 | P00519 | 1/20 | 0.48 |
| ▸ | BCR | P11274 | 1/20 | 0.48 |
| ▸ | SRC | P12931 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | ERN1 | O75460 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | KDM6B | O15054 | 1/20 | 0.48 |
| ▸ | KDM5C | P41229 | 1/20 | 0.48 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.48 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15997961 | 0.84 | ALDH1A1 (0.49) | GABRG2GABRB3GABRA5GABRA3CA12 | |
| SCHEMBL27040012 | 0.84 | ABL1 (0.52) | GABRG2GABRB3GABRA5GABRA3ALDH1A1 | |
| SCHEMBL27040114 | 0.84 | GABRG2 (0.50) | GABRG2GABRB3GABRA5GABRA3GRM5 | |
| SCHEMBL27040273 | 0.81 | ABL1 (0.60) | GABRG2GABRB3GABRA5GABRA3ALDH1A1 | |
| SCHEMBL5562975 | 0.81 | GRM5 (0.64) | GABRG2GABRB3GABRA5GABRA3GRM5 | |
| SCHEMBL67941 | 0.80 | CA12 (0.68) | GABRG2GABRB3GABRA5GABRA3CA12 | |
| SCHEMBL5563045 | 0.79 | GABRG2 (0.56) | GABRG2GABRB3GABRA5GABRA3GRM5 | |
| SCHEMBL5563766 | 0.79 | GABRG2 (0.56) | GABRG2GABRB3GABRA5GABRA3GRM5 | |
| SCHEMBL27715902 | 0.78 | CA12 (0.71) | GABRG2GABRB3GABRA5GABRA3CA12 | |
| SCHEMBL4895475 | 0.78 | GABRG2 (0.66) | GABRG2GABRB3GABRA5GABRA3GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | GABRG2 268/4885GABRB3 27/4885GABRA5 89/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.